At LabGenius Therapeutics ("LabGenius"), our mission is to discover the next generation of therapeutic antibodies by combining human and machine intelligence. To do this, we’ve pioneered the development of EVA™, state-of-the-art automated platform, enabling the closed-loop discovery of high-performing, non-intuitive antibody designs using proprietary, ML-grade datasets.
For our wholly-owned therapeutic pipeline, we’re using our closed-loop discovery engine to establish a pipeline of highly selective T-cell engagers and ADCs for the treatment of solid tumours.
LabGenius has raised >£55M and is backed by top-tier investors, including M Ventures, Octopus Ventures, LG Corp, Atomico, Kindred Capital, Lux Capital and Obvious Ventures amongst others.
The company is headquartered in London (UK) where we’ve established a cutting-edge antibody engineering facility. The company is staffed by a multidisciplinary team of more than 50 scientists and engineers.
As a Data Scientist at LabGenius, you will provide end-to-end data science support for at least one therapeutic asset as we aim to progress from lead discovery all the way to clinical trials. You will drive the “design” and “learn” cycles of the “design-build-test-learn” that forms the basis of our therapeutic antibody optimisation cycles at LabGenius, including the proposal of candidates for rapid experimental characterisation. You will enable a data-first ecosystem at LabGenius through your proficiency at processing complex datasets and extracting key insights.
Our Data Science (DS) and Machine Learning (ML) team pushes the boundaries of therapeutic antibody optimisation by integrating novel DS/ML/AI tooling with our leading experimental laboratory. We oversee the design and optimisation of both monovalent VHHs and multivalent T-cell engagers, including the analyses of experimental data and subsequent ML modelling. At LabGenius, these models allow us to design molecules with previously unexplored therapeutic potential. All the work we do is focused directly on how we can progress and improve getting our therapies closer to treating patients as quickly and safely as possible.
This is a hybrid role with a minimum of 3 days per week in the Bermondsey office and up to 2 days working from home.
Aside from being part of our brilliant, purpose-driven team, you’ll also enjoy:
Financial 💸
Health & Wellness 🍏
Time-Off ⏰
Wellbeing & Culture 💛
We believe that diverse perspectives build innovative, exceptional teams. As an equal opportunity employer, we do not discriminate on the basis of age, disability, gender reassignment, marriage and civil partnership, pregnancy and maternity, race (including colour, nationality, and ethnic or national origin), religion or belief, sex, sexual orientation, or any other protected characteristic.
If you don't feel like you meet every single requirement of this role, we still want to hear from you! We encourage you to apply, have a discussion with us about the role or others that we may have at LabGenius either now or in the future, together we can build more inclusive workplaces.

LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVA™, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVA™ is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.